Warning letter
Morton Grove Pharmaceuticals, Inc.: warning letter of Feb 17, 2017
FDA warning letter 505993 · Chicago District Office
Key facts
| Reference number | 505993 |
|---|---|
| Company | Morton Grove Pharmaceuticals, Inc. |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Feb 17, 2017 |
| Posted date | Feb 17, 2017 |
| Issuing office | Chicago District Office |
| Product type | Drugs |
| CFR sections cited | 211.68(b), 211.192, 211.22(d), 211.110(a), 211.110(c), 211.194(a), 211.180(e), 314.98(b) |
| Inspection city | Morton Grove |
| Inspection ZIP | 60053 |
| Inspection start date | Jan 4, 2016 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: